Loading stock data…
ANTX
$3.91+0.06 (+1.56%)
Market ClosedLast close Jun 9
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AN2 Therapeutics, Inc. in the Healthcare sector is trading at $3.91. Wall Street consensus targets $9.00 (1 analysts), implying a +130.2% move over the next 12 months. The stock is currently 43% below its 52-week high of $6.91, remaining 81.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +130.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Oversold momentum (RSI 32) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.91
Potential Downside
0%
Whystock Fair Value$3.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for pa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.26%
Volume
Today's trading volume
166,933
Recent News
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Positive Signs As Multiple Insiders Buy AN2 Therapeutics Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...